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Editorial Comment
Atrial Natriuretic Factor: A
Ventricular Hormone?*
ANDRE PASTERNAC, MD, FACC,t:j:
MARC CANTIN, MD, PHD:j:§
Montreal, Quebec, Canada
The adaptive mechanisms of the heart to chronic ventricular
overload have recently been reviewed (1). They include
ventricular hypertrophy; molecular changes in contractile
proteins, particularly the synthesis of fetal myosin isoforms
(2,3); and a complex reprogramming of cardiac gene expres-
sion (4). Experimental data also provide evidence of ventric-
ular activation of the atrial natriuretic factor (ANF) gene
(5-9). Children with congenital heart disease provide hemo-
dynamic models of pressure and volume overload, allowing
the study of the contribution of the atria and the ventricles to
ANF production.
Current study. In the current issue of the Journal, Ober-
hansli et al. (10) report the ANF plasma concentrations and
hemodynamic variables obtained from sequential measure-
ments from the inferior vena cava to the pulmonary artery, as
well as from the left atrium and the aorta, in young patients
with three types of conditions. Patients with tetralogy of
Fallot, that is, with right ventricular pressure overload, con-
stituted group I; patients with left to right shunt lesions and
pulmonary hypertension, that is, with ventricular volume
overload and a variable degree of right ventricular pressure
overload, constituted group II; and patients with minor car-
diac abnormalities constituted the control group. Group II
patients had significant enlargement of the left atrium com-
pared with that in the other two groups; these children had
significantly higher ANF levels and were well separated from
the control group but less well from those with tetralogy of
Fallot. In groups I and II there was a 50% increase in ANF
concentrations from the inferior vena cava to the right atrium
and a further 30% increase from the right atrium to the
pulmonary artery. Clearly, the distension of the left atrium
present in the group II patients but not in the patients with
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tetralogy of Fallot must account for a significant part of the
difference in ANF released. Is it, however, the only explana-
tion of the difference? In group I (patients with right ventric-
ular pressure overload and a normal-sized left atrium) plasma
levels of ANF tend to be increased because of right atrial and
probably right ventricular contributions, but the increase is
slight and variable. In group II (a less homogeneous group of
patients with a variable degree of right ventricular pressure
overload and a significant left ventricular volume overload, as
indicated by an enlarged left atrium and possibly a right
ventricular volume overload in some patients) ANF elevation
is significant and results presumably from contributions of the
right and left atria, and also from the right and left ventricles.
To test further the potential contribution of the right
ventricle, the authors (10) induced a temporary right ventric-
ular volume and pressure overload, which also resulted in an
increase in right atrial pressure. They observed an increase
in ANF levels between the right atrium and the pulmonary
artery in all groups, suggesting to the authors the existence
of a ventricular site for the production and release of the
hormone.
Several issues raised by this elegant study need to be
addressed: I) Can the conclusion that there is a ventricular
contribution to ANF release be accepted without data from
various sites in the coronary sinus system? 2) What is the
significance and role of ventricular ANF? 3) What are the
differences between atrial and ventricular ANF? 4) What are
the clinical implications of plasma ANF increases in com-
pensated congenital heart disease?
1. Is there a ventricular contribution to plasma ANF? The
significant increases in ANF levels between the inferior vena
cava and the right atrium and then between the right atrium
and the pulmonary artery suggest a significant contribution
by the blood from the coronary sinus. However, because
only one sample was taken in the right atrium, none in the
right ventricle and none in the coronary sinus system,
uncertainty persists about the precise origin of the hormone
sampled in the right atrium and the pulmonary artery.
However, because the anatomy of the venous drainage of
the heart has now been clarified (11) and demonstrated
angiographically (12) in the conscious adult human being, it
may in some instances be possible to document the origin of
ANF by selective blood sampling in the coronary sinus
system. The coronary sinus is the common terminal portion
of a number of variably developed veins. Its main tributaries
are the great cardiac vein, the posterior interventricular
vein, the posterior vein of the left ventricle, the oblique vein
of Marshall and the small cardiac vein (1 I). The anterior
interventricular vein which is situated in the anterior inter-
ventricular groove and is upstream of the great cardiac vein,
drains blood from the left ventricle but not from the atria
(13). Yasue et al. (13) have been able to document the release
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of ANF from the left ventricle in patients with dilated
cardiomyopathy by sampling blood for ANF levels from the
aorta, the coronary sinus, the great cardiac vein and the
anterior interventricular vein. There was a significant in-
crease in plasma ANF levels between the root of the aorta
and the anterior interventricular vein, and this correlated
well with impairment of left ventricular function (13). Al-
though admittedly difficult to accomplish in children with
congenital heart disease, in whom anatomic variations might
occur, similar sampling could confirm or exclude the contri-
bution of the left ventricle.
Venous drainage of the lateral wall of the right ventricle
occurs through the small cardiac vein and the right marginal
vein, which most often join to empty either into the coronary
sinus or directly into the right atrial cavity. The anterior
portion of the right ventricle drains through the anterior
cardiac vein, which empties directly into the right atrium or
may join the anterior interventricular vein (12). Selective
sampling of the drainage from the right ventricle might be
nearly impossible, because in only 25% of patients does the
small cardiac vein flow either directly into the coronary sinus
or enter it through a short portion of the posterior interven-
tricular vein (11). Ventricular biopsies may help demonstrate
conclusively the contribution of the ventricles to ANF
release.
The oblique vein of Marshall, which joins the great
cardiac vein to form the coronary sinus, is the principal
drainage vessel for left atrial venous blood. The left posterior
atrial veins also drain the left atrium and empty into the
coronary sinus. Venous drainage may also occur directly
into the left atrial cavity through the thebesian veins (14);
however, these veins are present only to a small and variable
extent in the left atrium (15). Catheterization of the oblique
vein of Marshall to explore ANF release by the left atrium,
although theoretically possible, has not been reported.
The primary means of drainage of right atrial wall blood is
still controversial. Part of the blood drains through the small
cardiac vein, which joins the proximal coronary sinus or
empties directly into the atrial cavity. In addition, a significant
fraction of venous blood is thought to drain directly into the
lumen of the right atrium through the thebesian veins (16).
2. Reinduction of ventricular ANF gene in ventricular
hypertrophy: significance and role of ventricular ANF. During
fetal development in rats ANF messenger ribonucleic acid
(mRNA) concentrations are similar in the atria and ventricles
(17,18), but these concentrations decrease precipitously in the
ventricles after birth, reaching levels that are at least 10 times
lower than those in the atria of adult rats (19). The decrease of
ANF messenger ribonucleic acid (RNA) and peptide from
ventricular muscle may reflect a tissue-specific inactivation of
the ANF gene after cessation of cardiac cell growth. How-
ever, a number of conditions are now known to produce an
elevation of both immunoreactive ANF and ANF messenger
RNA levels in the adult ventricles, both in vivo and in vitro
(4,5,20-25). A pronounced elevation of ventricular ANF
messenger RNA and immunoreactive ANF levels has been
shown to be associated with ventricular hypertrophy in vol-
ume-overloaded rats (5,21). Likewise, in hamsters with car-
diomyopathy an increase in ANF messenger RNA and pep-
tide occurs when compensatory cardiac hypertrophy
develops, and the increase takes place before the hemody-
namic changes observed in heart failure (20,22,23).
In persons with normal cardiovascular hemodynamics, the
ANF gene is expressed in both the ventricles and the atria,
but the concentration in the ventricles appears very low. With
the occurrence of heart failure, there is an increase in both
atrial and ventricular ANF gene expression (26,27). Saito et
al. (27) found that in patients with dilated cardiomyopathy or
with a previous myocardial infarction, ANF levels were
increased by two or three times in the atria compared with
levels in normal control subjects, whereas the levels in the
ventricles were 40 times higher than those ofcontrol subjects.
ANF messenger RNA levels in the ventricles of such patients
showed a to-fold increase compared with levels in normal
ventricles, and the total content in the ventricles reached
about 30% of that in the atria of the same heart.
Thus, these data suggest that the expression of the ANF
gene is reinduced in the ventricles of patients with conges-
tive heart failure (27). Furthermore, in keeping with experi-
mental data (13,28) that indicate that the expression of the
ANF gene is markedly increased in ventricles of spontane-
ously hypertensive rats and stroke-prone spontaneously
hypertensive rats with ventricular hypertrophy, the data of
Oberhansli et al. (10) suggest that a reinduction of the ANF
gene may also occur in compensated congenital heart dis-
ease with ventricular overload and some degree of ventric-
ular hypertrophy.
3. Differences between atrial and ventricular ANF. Bloch
et al. (18) have shown that in tissues and in primary cultures,
the neonatal atrial and ventricular cardiocytes differed in their
storage of ANF. Ventricular cardiocytes stored little ANF,
whereas atrial cardiocytes appeared to store the propeptide of
ANF. Thus, atrial and ventricular cardiocytes may release
ANF in different ways. Atrial cardiocytes secrete ANF by
means of a regulated pathway, because they store ANF,
contain abundant secretory granules and appear to respond to
appropriate stimuli. In contrast, neonatal ventricular cardio-
cytes appear to use a constitutive pathway for ANF secretion,
and they release ANF rapidly after synthesis. Theoretically,
therefore, an acute increase in volume or pressure overload
probably does not affect the level of ventricular ANF secre-
tion.
4. Clinical implications of increased ventricular ANF gene
expression in compensated congenital heart disease. It ap-
pears that in children with compensated heart disease, all
four chambers of the heart may, as in the rat (5), express the
ANF gene under conditions of pressure or volume overload.
Then, the human heart with ventricular hypertrophy, like the
hamster heart, may return to a fetal or neonatal type of ANF
secretion; the amount of ventricular immunoreactive ANF
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and ANF messenger RNA increases. and typical secretory
granules appear in approximately 20% of ventricular cardi-
ocytes. The increased ventricular ANF secretion may help
buffer the neurohormonal effects of congestive heart failure.
As congestive heart failure develops, the atrial contribution
to immunoreactive ANF production and total ANF messen-
ger RNA content appears to decrease, while the ventricles
appear to take over the production of ANF. In severe
congestive heart failure in the hamster, for instance, as much
as 74% of circulating ANF is produced in the ventricles.
Finally, the ratio of immunoreactive ANF levels to ANF
messenger RNA levels in the ventricles is much smaller than
that in the atria. This suggests a more rapid secretion of ANF
after synthesis in the ventricles and is consistent with a
constitutive type of secretion of immunoreactive ANF from
the ventricular cardiocytes (18).
Conclusions. Thus, these clinical data provide indirect
support for the experimental studies that have suggested that
ANF gene reprogrammingmay occur at the onset of ven-
tricular hypertrophy (5-9). In conjunction with other
changes involving in particular the adrenergic nervous sys-
tem, the aldosterone-renin-angiotensin system and the vaso-
pressin system, this may help prevent or delay the occur-
rence of congestive heart failure. Clearly. additional
research is needed to document better in the young and in
adults the ventricular origin ofANF and to understand better
both the regulation of its ventricular release and the mech-
anism of induction of the ventricular ANF gene. so that
therapeutic applications may be developed.
We are grateful to Dr. Nicolaas van Doesburg. Division of Cardiology, St.
Justine Hospital and the University of Montreal, for valuable comments and
suggestions.
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